Theratechnologies Stock Performance
| THTX Stock | USD 1.29 0.08 6.61% |
The entity has a beta of 0.85, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Theratechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Theratechnologies is expected to be smaller as well. Theratechnologies right now has a risk of 3.22%. Please validate Theratechnologies coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Theratechnologies will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Theratechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Theratechnologies is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:4 | Last Split Date 2023-07-31 |
1 | Theratechnologies Inc. Sees Significant Increase in Short Interest | 09/13/2024 |
2 | Theratechnologies annonce un risque dinterruption temporaire de lapprovisionnement dEGRIFTASV au dbut de 2025 | 09/17/2024 |
3 | Theratechnologies annoncera ses rsultats financiers du troisime trimestre de lexercice financier de 2024 et fera une mise jour de ses activits | 09/26/2024 |
4 | Earnings to Watch Theratechnologies Inc Reports Q3 2024 Result | 10/09/2024 |
5 | Will Theratechnologies turn things around in November | 10/10/2024 |
6 | Theratechnologies Issues Earnings Results | 10/11/2024 |
7 | Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multi... | 10/17/2024 |
8 | Theratechnologies Share Price Passes Above Fifty Day Moving Average - Time to Sell - MarketBeat | 11/14/2024 |
9 | Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review | 11/26/2024 |
| Begin Period Cash Flow | 23.9 M |
Theratechnologies |
Theratechnologies Relative Risk vs. Return Landscape
If you would invest 124.00 in Theratechnologies on September 3, 2024 and sell it today you would lose (3.00) from holding Theratechnologies or give up 2.42% of portfolio value over 90 days. Theratechnologies is currently generating 0.0133% in daily expected returns and assumes 3.2174% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Theratechnologies, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Theratechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theratechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Theratechnologies, and traders can use it to determine the average amount a Theratechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0041
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | THTX |
Estimated Market Risk
| 3.22 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Theratechnologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theratechnologies by adding Theratechnologies to a well-diversified portfolio.
Theratechnologies Fundamentals Growth
Theratechnologies Stock prices reflect investors' perceptions of the future prospects and financial health of Theratechnologies, and Theratechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theratechnologies Stock performance.
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 74.77 M | ||||
| Shares Outstanding | 45.98 M | ||||
| Price To Book | 20.13 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 81.76 M | ||||
| Gross Profit | 56.22 M | ||||
| EBITDA | (10.31 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 36.46 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 58.97 M | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 1.04 X | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (5.68 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 55.72 M | ||||
| Total Asset | 77.77 M | ||||
| Retained Earnings | (408.66 M) | ||||
| Working Capital | 16 M | ||||
About Theratechnologies Performance
Evaluating Theratechnologies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Theratechnologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Theratechnologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 101.49 | 106.56 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | 1.32 | 1.39 |
Things to note about Theratechnologies performance evaluation
Checking the ongoing alerts about Theratechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Theratechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theratechnologies may become a speculative penny stock | |
| Theratechnologies had very high historical volatility over the last 90 days | |
| Theratechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 81.76 M. Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 56.22 M. | |
| Theratechnologies currently holds about 36.46 M in cash with (5.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Latest headline from gurufocus.com: Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review |
- Analyzing Theratechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theratechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Theratechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theratechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theratechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Theratechnologies' stock. These opinions can provide insight into Theratechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Theratechnologies Stock Analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.